Trial Profile
An open label, randomized, 2 x 3 crossover study to evaluate bioequivalence between fixed-dose combination of SAH100 tablets (300/5/25mg aliskiren/amlodipine/HCTZ) and free combination of market formulation of 300mg aliskiren tablet, and clinical service formulations of 5mg amlodipine and 25mg hydrochlorothiazide in healthy subjects under light meal conditions
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2016
Price :
$35
*
At a glance
- Drugs Aliskiren/amlodipine/hydrochlorothiazide (Primary) ; Aliskiren; Amlodipine; Hydrochlorothiazide
- Indications Hypertension
- Focus Pharmacokinetics
- Sponsors Novartis
- 05 Oct 2011 New trial record